Shopping Cart 0
Cart Subtotal
USD 0

Lipocine Inc (LPCN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Lipocine Inc (Lipocine) is a pharmaceutical company that develops and commercializes treatment for men's and women's health. The company's pipeline products for men's health include LPCN 1111 and LPCN 1021; and for women's health include LPCN 1107. Its LPCN 1111 is an oral testosterone product candidate and LPCN 1021 is an oral testosterone replacement therapy with positive topline. Lipocine offers LPCN 1107, an oral hydroxyprogesterone caproate product for prevention of preterm birth. The company develops patented technology based on lipidic compositions that form optimal dispersed phase in the gastrointestinal environment for improved absorption of the insoluble drug. Its Lip'ral is a technology based on lipidic compositions that form optimal dispersed phase in the gastrointestinal environment. Lipocine is headquartered in Salt Lake City, Utah, the US.

Lipocine Inc (LPCN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Lipocine Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Lipocine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Lipocine Inc, Pharmaceuticals & Healthcare, Deal Details 11

Merger 11

Marathon Bar And Lipocine Complete Reverse Merger Transaction 11

Licensing Agreements 12

Lipocine Enters into Licensing Agreement with Spriaso 12

Equity Offering 13

Lipocine Plans to Raise up to USD10.8 Million in Public Offering of Shares 13

Lipocine to Raise USD20 Million in Public Offering of Shares 14

Lipocine Raises USD34.8 Million in Public Offering of Common Stock 15

Lipocine Completes Underwriters Exercise Of Full Over-Allotment Option Of Public Offering Of Shares For USD 14.2 Million 17

Lipocine Completes Private Placement Of Shares For USD 37.8 Million 18

Lipocine Inc-Key Competitors 19

Lipocine Inc-Key Employees 20

Lipocine Inc-Locations And Subsidiaries 21

Head Office 21

Other Locations & Subsidiaries 21

Recent Developments 22

Financial Announcements 22

Aug 07, 2018: Lipocine announces financial and operational results for the second quarter and six months ended June 30, 2018 22

May 07, 2018: Lipocine Reported Financial and Operational Results for the First Quarter Ended March 31, 2018 24

Mar 12, 2018: Lipocine Reports Financial and Operational Results for the Fiscal Year Ended December 31, 2017 25

Nov 08, 2017: Lipocine Announces Financial and Operational Results for the Third Quarter and Nine Months Ended September 30, 2017 26

Aug 07, 2017: Lipocine Announces Financial and Operational Results for the Second Quarter and Six Months Ended June 30, 2017 27

May 08, 2017: Lipocine Announces Financial and Operational Results for the First Quarter 2017 29

Mar 06, 2017: Lipocine Announces Financial and Operational Results for the Full Year of 2016 30

Corporate Communications 31

Feb 15, 2017: Lipocine Announces the Promotion of Gregory Bass to Chief Commercial Officer 31

Legal and Regulatory 32

Feb 16, 2018: Lipocine Announces Settlement of Securities Class Action Lawsuit 32

Sep 21, 2017: Lipocine Announces Motions Decision by USPTO in Interference Against Clarus 33

Product News 34

06/19/2017: Lipocine to Host Conference Call and Webcast to Discuss Top-Line Results From the Dosing Validation and Dosing Flexibility Studies of LPCN 1021 34

06/19/2017: Lipocine Validates "No Titration"Dosing Regimen With Positive Topline Efficacy Results for LPCN 1021, Oral Testosterone Candidate 35

Product Approvals 36

May 09, 2018: Lipocine Receives Complete Response Letter for TLANDO From U.S. Food and Drug Administration 36

Jan 10, 2018: Lipocine Announces Outcome of FDA Advisory Committee Meeting for TLANDO, Testosterone Replacement Therapy in Adult Males with Hypogonadism 37

Nov 17, 2017: U.S. FDA Extends Review for TLANDO; Advisory Committee Meeting Date of January 10, 2018 Remains Unchanged 38

Oct 18, 2017: FDA Advisory Committee Scheduled to Review TLANDO on January 10, 2018 39

Sep 20, 2017: Lipocine Announces FDA Advisory Committee Meeting for TLANDO 40

Aug 14, 2017: Lipocine Announces FDA Acknowledgement of TLANDO (LPCN 1021) NDA Resubmission; PDUFA Goal Date, February 8, 2018 41

Aug 09, 2017: Lipocine Resubmits NDA for Its Oral Testosterone Product Candidate, LPCN 1021, for Treatment of Hypogonadism 42

Clinical Trials 43

Jun 07, 2018: Lipocine Announces Dosing in Ambulatory Blood Pressure Study for TLANDO 43

Apr 24, 2017: Lipocine Completes Enrollment in the LPCN 1021 Fixed Dose Clinical Trials 44

Jan 05, 2017: Lipocine Initiates a Dosing Flexibility Study for LPCN 1021, Its Oral Testosterone Replacement Product Candidate 45

Other Significant Developments 46

Feb 08, 2018: Lipocine Announces USD 10 Million Loan and Security Agreement with Silicon Valley Bank 46

Appendix 47

Methodology 47

About GlobalData 47

Contact Us 47

Disclaimer 47


List Of Figure

List of Figures

Lipocine Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Lipocine Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Lipocine Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Lipocine Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Lipocine Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Lipocine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Marathon Bar And Lipocine Complete Reverse Merger Transaction 11

Lipocine Enters into Licensing Agreement with Spriaso 12

Lipocine Plans to Raise up to USD10.8 Million in Public Offering of Shares 13

Lipocine to Raise USD20 Million in Public Offering of Shares 14

Lipocine Raises USD34.8 Million in Public Offering of Common Stock 15

Lipocine Completes Underwriters Exercise Of Full Over-Allotment Option Of Public Offering Of Shares For USD 14.2 Million 17

Lipocine Completes Private Placement Of Shares For USD 37.8 Million 18

Lipocine Inc, Key Competitors 19

Lipocine Inc, Key Employees 20

Lipocine Inc, Other Locations 21

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Lipocine Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.